Table: Sapporo Clinical Lab - 6-MTH group results
Nov 10 (Reuters)-
Sapporo Clinical Laboratory Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2017 Sep 30, 2016 Mar 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 8.72 8.43 17.70
(+3.4 pct) (-1.9 pct) (+3.8 pct)
Operating 509 mln 350 mln 751 mln
(+45.5 pct) (-30.1 pct) (-2.6 pct)
Recurring 522 mln 370 mln 778 mln
(+41.0 pct) (-27.6 pct) (-3.1 pct)
Net 346 mln 239 mln 522 mln
(+44.7 pct) (-25.2 pct) (+1.8 pct)
EPS 99.62 yen 68.84 yen 150.28 yen
Ann Div 10.00 yen 10.00 yen
-Q2 div NIL NIL
-Q4 div 10.00 yen 10.00 yen
NOTE - Sapporo Clinical Laboratory Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=9776.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Sapporo Clinical Laboratory
See all newsTable: Sapporo Clinical Lab - 9-MTH group results
Table: Sapporo Clinical Lab - 6-MTH group results
Brief: Sapporo Clinical Laboratory Inc - To Retire Treasury Shares Worth 26% Of Outstanding Stock On Feb 17
Table: Sapporo Clinical Lab -Q1 group results
Table: Sapporo Clinical Lab -2024/25 parent results